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expression and mutation signatures may provide the
means of ultimately matching patients with treatment and
matching treatment with response mechanisms. Given
that relapsed disease appears to be chemoresistant across
multiple classes of therapy, integration of personalized
treatment is likely to be most effective when applied as
early as possible.
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Administration of passive antibodies through trans-fusion of plasma from donors recovering from a viralinfection has long been employed to treat individu-
als infected with the same pathogen.1 However, in studies
with convalescent plasma (CP), differences and inherent
limitations (e.g., sensitivity/specificity of  tests to quantify
neutralizing antibodies; sample size; scheduling of treat-
ment [early/late CP administration vs. degree of disease
severity], the presence of confounders [concomitant treat-
ments]), and restricted generalizability of data argued for
large-scale, randomized, controlled trials.1,2 The results of a
multicenter proof-of-concept, observational Italian study in
46 patients with moderate or severe acute respiratory dis-
tress syndrome due to infection with the novel coronavirus,
SAR-CoV-2, who needed mechanical ventilation and/or
continuous positive airway pressure are reported in this
issue of the Journal.3 The interval between symptom onset
and study inclusion was highly variable (2-29 days). The 7-
day mortality rate was 6% in patients given CP compared
with an expected 15% according to Italian statistics and
30% in a small concurrent cohort not treated with CP.
Weaning from continuous positive airway  pressure was
achieved in 26 of 30 patients, and three of the seven intu-
bated patients were extubated. Whether those who
received CP earlier improved more or faster than patients
who received plasma later in the course of the disease is not
clarified, nor are the reasons for administering one, two or
three CP bags provided. In this larger than previous uncon-
trolled reports, five serious adverse events (including 1
transfusion-related acute lung injury [TRALI]) occurred in
four patients. Although TRALI may be triggered by trans-
fused antibodies,4 CP was safe in this study as it was in
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Table 1. Summary on the use of convalescent plasma# in moderately to severely ill patients infected with major emerging viruses. 
Virus, Ref(s)                                   Design/Patients/Treatments/Objectives                                           Results/Interpretation/Limitations
SARS-CoV-2                                         Case series. 5 critically ill patients (36-65 years old, 2 women),              Following CP transfusion, body temperature normalized within
JAMA. 2020;323(16):1582-1589.           all with confirmed SARS-CoV-2 infection + ARDS, rapidly                         3 days (4/5 patients). Within 12 days, the SOFA score decreased;
                                                                   progressing severe pneumonia and high viral load despite                       PaO2/FiO2 increased (range, 284-366 after vs. 172-276 before);
                                                                   treatment; all receiving mechanical ventilation;                                           viral loads became negative, and SARS-CoV-2-specific and
                                                                   PaO2/FiO2 <300. 10-22 days after admission (mean, 18.2),                         neutralizing antibody titers increased (range, 1:80-1:320 on day
                                                                   patients received 400 mL CP with a SARS-CoV-2–specific                         7 vs. 1:40-1:60 before). ARDS resolved in 4 patients 12 days
                                                                   IgG binding titer ≥1:1000 and a neutralization titer ≥40.                             after transfusion, 3 patients stopped mechanical ventilation 
                                                                                                                                                                                                       within 2 weeks of treatment. 3/5 patients were discharged from 
                                                                                                                                                                                                       the hospital, 2 in a stable condition 37 days after CP.
SARS-CoV-2                               Prospective observational. 10 severely ill patients                                      By day 3 after CP transfusion, improved clinical symptoms and
Proc Natl Acad Sci U S A. 2020;           (34-78 years old) with confirmed COVID-19 infection.                               laboratory values, increases in neutralizing antibody titers,
117(17):9490-9496.                                Maximal supportive care + 200 mL CP (neutralizing antibody                  patients’ oxygen saturation and lymphocyte count; decreases
                                                                   titers >1:640) given to the patients 16.5 days (median) after                   in CRP, SARS-Cov-2 viral load, and radiological lung lesions 
                                                                   onset of illness. Primary endpoint: CP safety. Secondary                           (varying degrees of absorption of lung lesions within 7 days). 
                                                                   endpoints: improvement of symptoms and laboratory                               No severe adverse events following CP administration.
                                                                   parameters within 3 days after administration of CP.                                  
SARS-CoV-2                               Case reports. 4 critically ill patients (31-73 years old) with                       All recovered from the infection. Resolution or partial 
Chest. 2020;158(1):e9-e13.                  confirmed SARS-CoV-2 infection and respiratory failure requiring         absorption of lung lesions (all cases); reduced viral load 
                                                                   mechanical ventilation (ECMO in 2 cases) were given                               (2 cases), 3/4 discharged between days 18-43. 
                                                                   200-2400 mL of CP 11-18 days (mean: 15.25 days) after admission.          Recovery/discharge within 1 to 4 weeks after starting CP 
                                                                                                                                                                                                       transfusion; one patient discharged on supplemental oxygen, 
                                                                                                                                                                                                       another required continued critical care for multi-organ failure.
SARS-CoV-2                               Open-label, multicenter, randomized trial. The original sample               At the time of the termination, 103/200 patients (58.3% males,
JAMA 2020;324(5):460-470.                  size was 100 for each group to provide 80% power with a                          median age 70 years) had been enrolled. Of these, 98.1%
                                                                  two-sided significance level of α=0.05.                                                          (101/103) completed the trial. Within 28 days, clinical
                                                                   Patients (males/females, ≥18 years of age) with confirmed                     improvement was detected in 51.9% (27/52) in the CP group
                                                                   COVID-19 and severe ARDS and/or hypoxemia or life-threatening           vs. 43.1% (22/51) in the control group (HR, 1.40 [95% CI: 
                                                                   conditions (shock, organ failure, or requiring mechanical                        0.79-2.49]; P=0.26). Among those with severe disease, 
                                                                   ventilation) were stratified by age and disease severity.                           improvement was found in 91.3% (21/23) of the CP group vs.
                                                                   Intervention: 4-13 mL/kg volume of ABO-compatible                                  68.2% (15/22) in the control group (HR, 2.15 [95% CI: 
                                                                   CP with IgG titer ≥1:640 + standard treatment (vs. standard                   1.07-4.32]; P=0.03). Among those with life-threatening disease, 
                                                                   treatment alone). Primary outcome: time to improvement within          improvement was found in 20.7% (6/29) of the CP group vs. 
                                                                   28 days, secondary outcomes: 28-day mortality, time to discharge,         24.1% (7/29) in the control group (HR, 0.88 [95% CI: 0.30-2.63];
                                                                   negativity of viral PCR within 72 h of treatment. The study was                P=0.83). At day 28, there was no difference in mortality (15.7% 
                                                                   terminated early due to the containment of the SARS-CoV-2                   vs. 24.0%; OR, 0.65 [95% CI: 0.29-1.46]; P=0.30) or time to
                                                                   epidemic in China.                                                                                                discharge (51.0% vs. 36.0%; HR, 1.61 [95% CI: 0.88-2.93]; P=0.12). 
                                                                                                                                                                                                       CP treatment was associated with a higher 
                                                                                                                                                                                                       conversion rate to negative viral PCR at 72 h (87.2% in the CP 
                                                                                                                                                                                                       group vs. 37.5% in the control group (OR, 11.39 [95% CI: 3.91-
                                                                                                                                                                                                       33.18]; P<0.001). Two adverse events occurred in two patients
                                                                                                                                                                                                       in the CP group.  
SARS-CoV-2                               Multicenter, one-arm, interventional study. 46 patients, mean                 Patients had been symptomatic for a mean of 14 days 
Haematologica                                      62 years old (SD 11), 28 males (61%), confirmed SARS-CoV-2                  (SD, 7) and had had ARDS for a mean of 6 days (SD 3) prior
2020;105(12):2834-2840.                       infection + moderate-to-severe ARDS, elevated CRP and need                 to receiving CP. Three patients (6.5%) died within 7 days. 
                                                                   for mechanical ventilation and/or CPAP. 1-3 units (250-300 mL each)     Among survivors, PaO2/FiO2 increased by 112 units 
                                                                   of CP (neutralizing antibody titers: 1:80-1:320) +usual treatment.          (95% CI: 82-142); severity of radiological signs decreased
                                                                   Primary outcome: 7-day hospital mortality. Secondary outcomes:           in 23% (95% CI: 5-42%); CRP, ferritin and lactate dehydrogenase
                                                                   PaO2/FiO2 , laboratory/radiologic changes, weaning from mechanical     levels decreased by 60%, 36% and 20%, respectively. 
                                                                   ventilation, CP safety.                                                                                            Weaning from CPAP was achieved in 26/30 patients and 3/7 
                                                                                                                                                                                                       intubated patients could be extubated. Five serious adverse 
                                                                                                                                                                                                       events occurred in four patients (1 TRALI), of which two were 
                                                                                                                                                                                                       possibly treatment related.
Influenza A or B §                    Randomized, double-blind phase III prospective trial. Patients               92/138 randomized to the high-titer, 48/138 to the low-titer group.
Lancet Respir Med.                              of all ages with severe influenza A infection; onset of illness                   At baseline, 60 (43%) participants were in intensive care; 55/78
2019;7(11):941-950.                               within 6 days of randomization. Randomization based on disease           (71%) of participants were not in intensive care requiring
                                                                   severity and age (< vs. >18 years): either two units (or pediatric          oxygen. Early termination.  No superiority of high-titer over 
                                                                   equivalent) of high titer (≥1:80) or low titer (≤1:10)                                 low-titer plasma (OR on day 7: 1.22; 95% CI: 0.65-2.29, P=0.54).
                                                                   anti-influenza virus hemagglutinin antibodies CP; 28 days of                    34% of participants (47/138) experienced 88 serious adverse 
                                                                   follow-up. Objectives: efficacy of high-titer vs. low-titer CP.                      events, including ARDS. Ten patients died (6 [7%] in the
                                                                                                                                                                                                       high-titer group, 4 [9%] in the low-titer group, P=0.73), 
                                                                                                                                                                                                       worsening of ARDS was the most common cause of death.  
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Virus, Ref(s)                                   Design/Patients/Treatments/Objectives                                           Results/Interpretation/Limitations
Influenza A or B §                   Randomized, double-blind, placebo-controlled trial. Adults                      156 received 500 mL of H-Ig, 152, placebo (224/308 influenza A 
Lancet Respir Med.                              (≥18 years of age), confirmed severe influenza A or B infection             serotypes and 84/308 influenza B serotypes). Clear rise in 
2019;7(11):951-963.                               needing hospital treatment, symptoms starting within 7 days                  hemagglutination inhibition titers against influenza A; smaller 
                                                                   before randomization, assigned to standard care (which included         rise in influenza B titers in the treated group. In subgroup
                                                                   antiviral therapy) + either 500 mL infusion of high-titer H-Ig                  analyses, the OR was 0.94 (0.55-1.59) in patients with influenza A
                                                                   (0.25 g/kg bodyweight, 24·75 g maximum) or saline placebo.                    and 3.19 (1.21-8.42) in those with influenza B (interaction 
                                                                   Primary outcome: clinical status at day 7.                                                       P=0.023). Through 28 days of follow-up, 47/156 (30%) of patients
                                                                                                                                                                                                       in the H-Ig group and 45/152 (30%) in the placebo group died or 
                                                                                                                                                                                                       experienced a serious adverse event (HR 1.06, 95% CI: 0.70-1.60; 
                                                                                                                                                                                                       P=0.79). 
Influenza A or B §                   Randomized, open-label, multicenter, phase II retrospective trial.        Respiratory status normalized in 28/42 (67%) of the participants 
Lancet Respir Med.                              Hospitalized patients with severe (hypoxia/tachypnea) influenza A        in the plasma group vs. 24/45 (53%) in the standard care alone
2017;5(6):500-511.                                  or B assigned on day 0 to standard care ± 2 units                                       group (HR: 1.71, 95% CI: 0.96-3·06, P=0.069). One patient in the
                                                                   (225–350 mL/unit or 8 mL/kg pediatric equivalent) of compatible           plasma group, and five (10%) in the standard care group died 
                                                                   anti-influenza plasma hemagglutination inhibition antibody                     (HR 0·19 [95% CI: 0·02-1.65], P=0·093). No difference between 
                                                                   titers ≥1:80 CP, follow-up: 28 days. Objectives: time to                               groups in days of hospital stay (median, 6 days vs. 11 days, 
                                                                   normalization of respiratory status by day 28 of hospitalization.              P=0.13) or in mechanical ventilation (median, 0 days vs. 3 days, 
                                                                                                                                                                                                       P=0.14). Serious adverse events including ARDS lower in the 
                                                                                                                                                                                                       plasma group than in the standard care group (9/46 [20%] vs. 
                                                                                                                                                                                                       20/52 [38%], P=0.041.
Influenza A (H1N1) °^            Prospective cohort study. Within 7 days of symptom onset,                      20/93 patients (21.5%) received CP. Mortality was lower in the
Clin Infect Dis 2011;52:447-456.          93 patients ≥18 years old with severe H1N1 2009 infection                       treatment group than in the matched control group (20.0% vs. 
                                                                   needing intensive care were given the possibility of a 500 mL                 54.8%; P=0.01, OR, 0.20; 95% CI: .06-.69; P=0.011). CP-treated 
                                                                   CP infusion over a 4 h period (neutralizing antibody titer  ≥1:160).        individuals showed significantly lower viral loads, and 
                                                                                                                                                                                                       post-treatment levels of interleukin-6, interleukin-10 and tumor 
                                                                                                                                                                                                       necrosis factor-α than those who refused CP treatment 
                                                                                                                                                                                                       (P<0.05). 
Influenza A (H1N1) °^            Multicenter, prospective, double-blind, randomized controlled               Patients receiving H-Ig had lower post-treatment (days 5 and 7)
Chest. 2013:144(2):464-473.                trial. Patients with severe H1N1 infection on standard antiviral               viral loads than controls (P=0.04 and P=0.02, respectively).
                                                                   treatment requiring intensive care and ventilatory support                      Initial serum cytokine level, significantly higher in the H-Ig
                                                                   randomized to receive one dose of 0.4 g/kg of H-Ig (17 patients)           group, fell to control levels 3 days after treatment. In patients 
                                                                   or 0.4 g/kg normal intravenous immunoglobulins                                         receiving treatment within 5 days of symptom onset, H-Ig was 
                                                                   (18 matched patients) over a period of 4 h.                                                  the only factor related to mortality (0% vs. 40%, respectively, OR,
                                                                                                                                                                                                       0.14; 95% CI: 0.02-0.92; P=0.04). No treatment-related adverse 
                                                                                                                                                                                                       events.
Ebola virus disease^^             Non-randomized, comparative study. Patients of various ages,                84 patients treated with plasma included in the analysis. From 
N Engl J Med. 2016;374(1):33-42,      confirmed EVD, two consecutive transfusions of 200 to 250 mL              day 3 to day 16 after diagnosis, the risk of death was 31% in the 
N Engl J Med. 2017;376(13):1297.      of ABO-compatible CP with varying levels of neutralizing                          CP group vs. 38% in the control group (risk difference, -7%; 95%
                                                                   antibodies. Transfusions initiated up to 2 days after diagnosis.                CI: -18 to 4). No serious adverse reactions were associated with
                                                                   Controls: 418 patients who had been treated at the same center           the use of CP. CP treatment was not associated with a
                                                                   during the previous 5 months. Primary outcome: risk of death                significant improvement in survival, in patients with confirmed
                                                                   from 3 to 16 days after diagnosis, adjustments for age; patients             EVD. However: (i) three-fourths of CP donors had low titers of
                                                                   who died before day 3 excluded.                                                                       neutralizing antibodies (1:10-1:40), only a minority (5%) had 
                                                                                                                                                                                                       higher titers (1:160), and (ii) patients receiving plasma with 
                                                                                                                                                                                                       high doses anti-Ebola virus IgG antibodies had larger decreases
                                                                                                                                                                                                       in viral loads. 
Ebola virus disease^^ &          Case series. Patients treated vs those who did not receive 1 unit          Compared with 25 non-treated patients, improved survival was 
J Infect. 2017;74(3):302-309.               (450 mL) of ABO-compatible convalescent whole blood (CWB)              documented in 44 subjects who received CWB (deaths, 44%  vs.
                                                                   within the first 24 h of admission over a period of 1-4 h.                          27.9%, respectively; odds ratio: 2.3, 95% CI: 0.8-6.5). There were 
                                                                                                                                                                                                       significant difference between viral load on admission and 
                                                                                                                                                                                                       after 24 h of treatment with CWB (P<0.01). No adverse events. 
SARS-CoV-1 *§§                                   Retrospective. 19 patients (38.7±12.39 years old) given 200-400 mL       Discharge at the end of a 3-week hospitalization in 74% of
Clin Microbiol Infect.                           CP (coronavirus titer range 1:160-1: 2560) compared to 21 patients       subjects receiving CP and in 19% of those on
2004;10(7):676-678.                               (47.9±19.60 years old) given methylprednisolone pulses.                          methylprednisolone. Mortality: 0/19 (CP group) vs. 5/21 
                                                                                                                                                                                                       (steroid group). Unknown titer or type of antibodies affecting 
                                                                                                                                                                                                       outcomes. Anti-SARS-CoV-1 antibodies contained within the CP 
                                                                                                                                                                                                       not standardized. 
SARS-CoV-1 *§§                       Retrospective. Patients (n=33/80) given CP (median volume                   At completion of a 3-week hospitalization, compared to the
Eur J Clin Microbiol Infect Dis.         279 mL, coronavirus titer range, 1:160-1:2,560) within day 14 after           overall SARS-related mortality for admitted patients 
2005;24(1):44-46.                                    the onset of symptoms vs. patients given CP more than 14 days             (17%, n = 299), those receiving plasma earlier had a lower
                                                                   after hospital admission.                                                                                    mortality rate (12.5%). No adverse events reported. 
                                                                                                                                                                                                       No correlation between clinical response and antibody titers 
                                                                                                                                                                                                       or transfused volumes. 
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#Donor selection is critical for the safety of plasma and plasma products. For SARS-CoV-2 studies; the FDA established that plasma should be collected from patients who had recovered from
COVID-19 who had a negative SARS-CoV-2 polymerase chain reaction test and had been symptom-free for at least 14 days. Donors should meet the eligibility criteria for standard blood donors
as set out in federal regulation 21 CFR 630.10 and 21 CFR 630.15, and standard testing should follow regulation 21 CFR 610.40. § A meta-analysis of studies published between 1918 and 1925 on
the so-called Spanish influenza pneumonia (Ann Intern Med. 2006;145(8):599-609), revealed lower case-fatality rates in patients receiving CP than in controls (16% vs. 37%, respectively); maximal
benefit being found in those receiving early treatment compared to patients who were transfused later (19% vs. 59%, respectively).  §§Case reports and case series concerning the Middle East
respiratory syndrome coronavirus (MERS-CoV) responsible for the 2015 MERS did not show clinical improvement with the administration of CP,  and raised the issue of the quality of plasma and
the role of neutralizing antibody titers in studies of CP (Sci Rep. 2016;6:25359, Emerg Infect Dis. 2015;21(12):2186-2189).  ° Data from this prospective, non-randomized trial are in keeping with
information of a contemporary retrospective observational study in the setting of H1N1 (Hong Kong Med J. 2010;16(6):447-454). Comparable support stems from case reports and case series of
the 2006 avian influenza A/H5N1 outbreak and the 2015 outbreak influenza A (H7N9) ( Hong Kong Med J. 2006;12:489; N Engl J Med. 2007;357:1450-1451; Int J Infect Dis. 2015;41:3-5; PLoS One.
2008;3:e2985). The latter studies also call for selecting convalescent donors based on the viral sequence of individual patients, a key issue for infections, such as influenza, caused by multiple
strains of viruses. ^ The overall evidence that the administration of CP,  serum, or H-Ig might be beneficial for the treatment of severe acute respiratory infections due to influenza or SARS-CoV-1
has been systematically reviewed and meta-analyzed (J Infect Dis. 2015;211(1):80-90).  As a whole,  a 75% reduction in the odds of mortality was found among patients with severe acute respira-
tory infections of viral etiology who were treated with convalescent plasma (or serum), together with a clinically relevant impact of the treatment on reducing the viral load. No evidence of seri-
ous adverse events or complications due to therapy were found and there was some evidence of a reduced use of critical care resources and length of hospital stay. Maximal reduction in mor-
tality was achieved when CP was administered early after symptom onset. ^^The efficacy of CP in Ebola virus disease has been reported in two case series (Clin Infect Dis. 2015;61(4):496-502, N
Engl J Med. 2016;374(7):636-646).  & In addition to Ebola virus disease, CP has been evaluated in the treatment of other viral hemorrhagic fevers e.g.  Bolivian (Am J Med. 1966;40(2):217-230),
Argentine (Presse Med. 1986;15(45):2239-2242.), and Lassa fever (Trans R Soc Trop Med Hyg. 1984;78(3):319-324). Inherent limitations and confounders compel caution in the analysis of these
small studies.                 *Data from case reports (Transfus Apher Sci. 2003;29(1):101; Hong Kong Med J. 2003;9(3):199-201; Zhonghua Yi Xue Za Zhi. 2003;83(12):1018-1022) and case series (J
Antimicrob Chemother. 2005;56(5):919-922) are in keeping with information from retrospective, non-randomized studies, in this setting.  SARS-CoV-2: severe acute respiratory syndrome of the coro-
navirus 2019, which causes COVID-19; SARS-CoV-1: 2003 severe acute respiratory syndrome-associated coronavirus 1 outbreak in Hong Kong; EVD: Ebola virus disease; ARDS: acute respiratory
distress syndrome; PaO2/FiO2: ratio of partial arterial oxygen pressure to fraction of inspired oxygten; TRALI: transfusion-related acute lung injury (whose features are similar to those of SARS-CoV-
2 infection); SOFA: Sequential Organ Failure Assessment; ECMO: extracorporeal membrane oxygenation support; CPAP: continuous positive airway pressure; H-Ig: hyperimmune immunoglobulin;
CP: convalescent plasma; CRP: C-reactive protein; OR: odds ratio; HR: hazard ratio; CI: confidence interval; SD: standard deviation; PCR: polymerase chain reaction. 
Table 2. Major emerging viruses potentially transmitted by blood and plasma products.§
Major pathogens                Description                                                    Epidemiology                                    Detection method             Inactivation/elimination method
Enveloped viruses
West Nile virus                       Flavivirus causing encephalitis                             South Europe, Africa, Americas          NAT, antibody IgM*              Solvent/detergent, heat
Dengue virus                           Flavivirus causing myalgia, arthralgia,                 South Asia, South America, Africa       NAT/antigen antibody.          Solvent/detergent, heat
                                                    hemorrhagic fever                                                   
Chikungunya virus                  Alphavirus causing arthralgia                                South Asia, Africa                                    NAT/antibody.                         Solvent/detergent, heat
Hepatitis B virus escape      Causes hepatitis, hepatocarcinoma                    Asia, Americas, Europe                          NAT/sequence HBsAg.         Heat, vaccination.
variants                                     
Non-enveloped viruses
Parvoviruses                            Cause myalgia, anemia, fetal malformation      Worldwide                                                 NAT/antibody                         Prolonged heat
Enterovirus                              Picornaviruses causing pharyngitis, myalgia,    Worldwide                                                 NAT                                          Heat
                                                    neuritis, encephalitis
Circoviruses                            No known disease                                                   Unknown                                                   NAT/PCR                                 Heat
Major emerging prions 
Variant Creutzfeldt-Jakob    Prion infectivity in brain, lymphoid tissues,      Europe, North America, Japan,           No screening test;                Resists conventional forms 
disease prion†                                         and blood                                                                   Taiwan, Saudi Arabia.                              diagnosis by                           of inactivation
                                                                                                                                                                                                             histopathology and
                                                                                                                                                                                                               western blot of brain 
                                                                                                                                                                                                               or tonsils after onset 
                                                                                                                                                                                                               of symptoms
§ The term “Emerging” denotes those pathogens whose incidence in humans has increased or may increase in the future, based on their appearance in a new host population or changes in epi-
demiology in an existing population. This definition includes causative agent(s) leading to a new infection, a re-emerging infection, or an infection with new attributes (e.g., drug resistance or
virulence) making them pathogenic. Like SARS-CoV-2, most of these previously unknown entities are capable of quickly overcoming the original geographical boundaries and spreading among
the human population. In the globalized world of the third millennium, millions of people and huge amounts of merchandise are transported every day by air from one part of the planet to
another. This facilitates the 'traffic' of microbes and the diseases they cause from ecological niches in which they were confined, and their rapid spread to every corner of the earth. Unpredictable
global and national events (wars, world tourism, migration) can further increase the spread of blood-borne diseases. With regards to the roles of zoonotic transmission in the introduction of an
unknown pathogen into a new human host population, recombination and re-assortment (adaptation) to produce ‘new’ mutations  that allow pathogens to acquire new biological characteristics
to adapt to new ecologies and to infect new hosts (dissemination), leading to short, explosive outbreaks (e.g. Ebola virus) or slower, silent spreading (e.g. HIV-1) have been documented. Factors
that influence the course of the SARS-CoV-2 disease are largely unknown.  Suggested reading: Nature. 2004;430(6996):242-249; Nat Med. 2004;10 (12 Suppl):S70-76; Nature. 2007;447(7142):279-283;
Nature. 2008;451(7181):990-993; Blood Transfus. 2009;7(3):167-171; Semin Thromb Hemost. 2013;39(7):779-793; Haematologica 2013;98(10):1495-1498. *Strategy currently only used in North
America and Canada, †Only four cases reported. IgM: immunoglobulin M; NAT: nucleic acid testing; PCR: polymerase chain reaction.
5,000 patients in another study.5 Also considering a
risk/benefit analysis performed to improve the treatment of
severe acute respiratory distress syndrome caused by
SARS-CoV-2 infection,1 the Food and Drug Administration
(FDA) issued guidance on CP collection and distribution in
the USA and recommended conducting clinical trials with
CP in the setting of SARS-CoV-2 infection.6 It has been pro-
posed that, in such trials, one CP unit is used for post-expo-
sure prophylaxis and one to two units for treatment of
SARS-CoV-2 infection.1 For patients who fail to meet the
criteria for enrollment in clinical trials, the FDA has
approved protocols for emergency use and expanded
access.4 In parallel, the plasma industry joined forces (the
CoVIg-19 ALLIANCE) to increase plasma collection and
produce safe and effective CP and hyperimmune
immunoglobulins (H-Ig).7,8 Beside the USA, other countries9
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are collecting CP to be used in SARS-CoV-2 infections, and
many studies are ongoing.10
Parallel to the submission of the Italian study, an open-
label, multicenter, randomized trial from China appeared,
in which patients with SARS-CoV-2 and severe acute respi-
ratory distress syndrome were randomized to 4-13 mL/kg
of CP plus standard treatment vs. standard treatment alone
(Table 1). The calculated sample size was 100 patients for
each group. Due to the containment of the SARS-CoV-2
epidemic in China, the study was terminated when 103 of
the 200 planned patients had been enrolled. At termination
of the trial, improvement was found in 21/23 patients in the
CP group vs. 15/22 in the control group (P=0.03) among
those with severe disease, and in 6/29 of the CP group vs.
7/29 in the control group (P=0.83) among those with life-
threatening disease. There was no between-group differ-
ence in mortality (P=0.30) and two adverse events were
detected in two patients in the CP group. 
While antibody administration by means of CP is indeed
a reliable strategy for conferring immediate immunity
against viral agents to individuals with SARS-CoV-2 infec-
tion, there is uncertainty about whether CP or H-Ig is the
more effective product to be administered.10,11 While CP is
characterized by donor-dependent variability in antibody
specificity and titers, H-Ig contains standardized antibody
concentrations. On the other hand, while the IgM fraction,
a key weapon against some viruses, is removed from plas-
ma during H-Ig fractionation, CP also provides coagulation
factors (to fight hemorrhagic fevers, such as Ebola).2
Although specific antibodies hamper viral replication, the
SARS-CoV spike (S) protein is the main antigenic compo-
nent responsible for biological effects, e.g., host immune
responses, neutralizing-antibody formation, T-cell respons-
es and ultimately protective immunity.12 On the whole, the
proportion of anti-S protein antibodies, relationships
between IgG/IgA/IgM, standardization of antibody titers
and optimal dosing and scheduling of CP administration are
still major unknowns from studies conducted so far in the
frame of the SARS-CoV-2 pandemic. 
This scenario of growing interest from clinicians,
patients, policy-makers, health systems and pharmaceutical
industries provides an unprecedented  opportunity to exert
a major imprint on the practice of medicine.2 A concerted
effort is warranted to achieve globally uniform, high-quali-
ty standards for CP or H-Ig preparations. In high-income
countries, the industrial production of plasma-derived prod-
ucts has never been safer than nowadays both because of
the guidelines produced by the FDA and European
Medicines Agency on donor selection and screening and
because of the availability of viral inactivation methods.
Plasma is collected at plasmapheresis centers using tech-
nologies regularly inspected by governing bodies before
approval for commercial use. Plasma is screened after each
donation and re-screened in mini-pools for human immun-
odeficiency virus-1, hepatitis A, B and C viruses, and par-
vovirus B19, and Plasma Master Files are subject to yearly
approval by regulatory agencies.13 Once collected, plasma
from single donors may be administered directly to patients
or pooled to manufacture plasma-derived products such as
H-Ig, coagulation factors and others. The resulting products
may be treated with solvent/detergent and/or super-heated
(at 80° C for 3 days), pasteurized or nano-filtered. The
aforementioned approaches are highly effective in mini-
mizing pathogen transmission, as demonstrated by the fact
that no blood-borne pathogen transmission has been
reported since 1987 for commercially prepared plasma
products received by patients with hemophilia, the epitome
of multi-transfused patients.13 In theory, however, risks
remain pertaining to emerging and re-emerging pathogens
(prions, non-lipid enveloped viruses) (Table 2), for which
diagnosis and inactivation methods are still a challenge.14
The reasons for this caveat concerning risks include the lack
of reliable screening tests for some pathogens (e.g. prions),
no screening for unknown pathogens, and relative poor
sensitivity/specificity of the available assay methods.15
Furthermore, some viral mutants may escape screening,16
which may also not pick up potential plasma contamina-
tion from infectious but not yet seropositive donors. In
addition, there may be low-level chronic carriers among
donors who remain undetected and yet contribute to infect
the plasma pool.17,18 Finally, determining the prevalence of
emerging pathogens may be difficult when there is a long
latency between infection and symptom onset.19
On this background and with these knowledge gaps, the
adaptation of screening methods is a constant challenge,13
and public health organizations and plasma pharmaceutical
industries have combined efforts to tackle the risks. In the
framework of its global perspective, the World Health
Organization tries to minimize pathogen transmission
through early information and public health vigilance on
the emergence of regional pathogens capable of causing
transfusion-transmitted infections (e.g. Zika virus in Brazil),
even before local authorities manage to develop means to
prevent blood-borne transmission.20 Because ‘zero risk’ in
terms of product safety is unlikely, governing bodies pro-
vide guidance to identify factors relevant for pathogen
transmission. As an example, the presence of blood-borne
hepatitis E virus may pose significant threats to some peo-
ple (e.g., the elderly, immunocompromised individuals)
despite being of low risk to other potential recipients. Thus,
in addition to the circumstances under which blood prod-
ucts are collected and manufactured, the nature of the
pathogen (e.g., its physical characteristics, level of virulence,
prevalence) and the patients’ characteristics (age, immune
status, geographical location, lifestyle, treatment urgency)
should be considered when choosing the individual treat-
ment (and assessing an acceptable level of risk). 
Alongside this scenario of basically satisfactory blood
product safety in high-income countries, it should be con-
sidered that in most low/middle-income countries proce-
dures for blood collection are seldom standardized, and
donor selection, screening and viral inactivation often fail to
meet the criteria validated and implemented by regulatory
agencies in high-income countries. If insufficient anti-
SARS-CoV-2 CP is available from high-income countries to
meet global needs, the use of plasma from low/middle-
income countries may become necessary but may also raise
some issues, because the type and prevalence of infectious
agents likely differ in different  populations.13
To sum up, if worldwide uniform advancements in
blood-banking quality are encouraged in low/middle-
income countries, there is now a global opportunity to per-
form clinical studies on the efficacy of CP or H-Ig in viral
infections and address uncertainties on the occurrence of
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serious adverse events related to the administration of these
products.10 Removing regulatory barriers that limit the use
of pathogen-reduction technology for CP collections would
be a major help in this respect.2 The process of obtaining
informed consent requires communication of risks and ben-
efits of treatments to patients. SARS-CoV-2 is an easily
inactivated enveloped virus,13 and strict regulations for plas-
ma product manufacturing minimize the risk of known and
unknown pathogens. Apart from emergency situations, the
extent to which people should be further informed on spe-
cific risks associated with any particular product will
depend on a variety of factors including availability of alter-
native treatments, and the patients’ characteristics (e.g., age,
physical/mental condition, education/level of understand-
ing, language barriers/religious beliefs). A good understand-
ing by health care professionals of the sources and modes
of production of plasma derivatives and of pathogen-reduc-
tion/inactivation techniques might be an additional benefit
of studies involving CP.
Addendum
Parallel to the submission of this Editorial, a systematic review
of completed (as of June 4, 2020) and ongoing (n=98) studies on
the efficacy and safety of convalescent plasma or hyperimmune
immunoglobulins to reduce mortality in patients with SARS-
CoV-2 infection appeared (Cochrane Database Syst Rev.
2020;7(7):CD013600. Its provisional conclusions support the
clinical relevance of the concepts summarized in the present
report.
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